Resistin level in coronary artery disease and heart failure: The central role of kidney function

Journal of Cardiovascular Medicine

Volumn 14, Issue 2, 2013, Pages 150-157

  Baldasseroni, Samuele ^a   Mannucci, Edoardo ^a   Di Serio, Claudia ^a   Orso, Francesco ^a   Bartoli, Nadia ^a   Mossello, Enrico ^a   Foschini, Alice ^a   Monami, Matteo ^a   Valoti, Paolo ^a   Fumagalli, Stefano ^a   Colombi, Claudia ^a   Pellerito, Silvia ^a   Gensini, Gianfranco ^a   Marchionni, Niccolò ^a   Tarantini, Francesca ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

adipokine; chronic heart failure; coronary artery disease; kidney function; resistin

Indexed keywords

ADIPOCYTOKINE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DIGOXIN; RESISTIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CORONARY ARTERY DISEASE; DEPRESSION; DRUG USE; FEMALE; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; MALE; MIDDLE AGED; OUTPATIENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESISTIN; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 84873090731     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e32834eec93     Document Type: Article

References (42)

1. Ronti T, Lupatelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 2006; 64:355-365.
2. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-b selectively impair insulin action on glucose production. J Clin Invest 2003; 111:225-230.
3. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as regulator of inflammation: implications for various human pathologies. Clin Immunol 2009; 133:157-170.
4. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
5. Reilly MP, Lehrke M, Wolfe ML, et al. Resistin in an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111:932-939.
6. Savage DB, Sewter CP, Klenk ES, et al. Resistin /Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50:2199-2202.
7. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006; 69:76-85.
8. Kralisch S, Sommer G, Stangl V, et al. Secretory products from human adipocytes impair endothelial function via nuclear factor kappaB. Atherosclerosis 2008; 196:523-531.
9. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108:736-740.
10. Calabro P, Samudio I, Willerson JT, Yeh HT. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110:3335-3340.
11. Rothwell SE, Richards AM, Pemberton CJ. Resistin worsens cardiac ischaemia-reperfusion injury. Biochem Biophys Res Commun 2006; 349:400-407.
12. Pischon T, Bamberger CM, Kratzsch J, et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005; 13:1764-1771.
13. Chu S, Ding W, Li K, Tang C. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008; 72:1249-1253.
14. Weikert C, Westphal S, Berger K, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008; 93:2647-2653.
15. On YK, Park HK, Hyon MS, Jeon ES. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007; 71:868-873.
16. Lee SH, Ha JW, Kim JS, et al. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: data from infarction prognosis study registry. Coron Artery Dis 2009; 20:33-39.
17. Frankel DS, Vasan RS, D'Agostino RB Sr, et al. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009; 53:754-762.
18. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-min walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985; 132:919-923.
19. Lang RM, Bierig M, Devereux RB, et al. Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
20. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary [update 2005]: The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-1140.
21. Di Bari M, Pozzi C, Cavallini MC, et al. The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the ICARe Dicomano study. J Am Coll Cardiol 2004; 44:1601-1608.
22. Greenfield S, Blanco DM, Elashoff RM, Ganz PA. Development and testing of a new index of comorbidity. Clin Res 1987; A35:346.
23. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17:37-49.
24. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-1197.
25. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
26. Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on atherothrombosis inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54:2129-2138.
27. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300:472-476.
28. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174:5789-5795.
29. Xu W, Yu L, Zhou W, Lou M. Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun 2006; 351:376-382.
30. Collot-Teixeira S, Martin J, McDermott-Roe C, et al. CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007; 75:468-477.
31. Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45:270-280.
32. Heilbronn LK, Rood J, Janderova L, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004; 89:1844-1848.
33. Yaturu S, Daberry RP, Rains J, Jain S. Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine 2006; 34:219-223.
34. Koch A, Gressner OA, Sanson E, et al. Serum resistin levels in critically ill patients are associated with inflammation, organ dysfunction and metabolism and may predict survival of nonseptic patients. Crit Care 2009; 13:1-9.
35. Takeishi Y, Niizeki T, Arimoto T, et al. Serum resistin is associated with high risk in patients with congestive heart failure: a novel link between metabolic signals and heart failure. Circ J 2007; 71:460-464.
36. Ellington AA, Malik AR, Klee GG, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007; 50:708-714.
37. Axelsson J, Bergsten A, Qureshi AR, et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006; 69:596-604.
38. D'Apolito M, Du X, Zong H, et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest 2010; 120:203-213.
39. Graveleau C, Zaha VG, Mohajer A, et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 2005; 280:31679-31685.
40. Cohen G, Ilic D, Raupachova J, Horl WH. Resistin inhibits essential functions of polymorphonuclear leukocytes. J Immunol 2008; 181:3761-3768.
41. Fildes JE, Shaw SM, Yonan N, Williams SG. The immune system and chronic heart failure: is the heart in control? J Am Coll Cardiol 2009; 53:1013-1020.
42. Vredevoe DL, Woo MA, Doering LV, et al. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1998; 82:323-328.